TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $888,860 | -55.4% | 99,425 | +12.3% | 0.00% | -100.0% |
| Q2 2023 | $1,991,378 | 0.0% | 88,545 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,991,378 | +48.9% | 88,545 | +39.3% | 0.00% | 0.0% |
| Q4 2022 | $1,337,045 | -99.9% | 63,578 | +1.8% | 0.00% | 0.0% |
| Q3 2022 | $1,538,177,000 | -4.1% | 62,426 | -5.7% | 0.00% | 0.0% |
| Q2 2022 | $1,603,177,000 | -7.4% | 66,165 | -1.5% | 0.00% | 0.0% |
| Q1 2022 | $1,731,255,000 | -11.7% | 67,181 | +6.3% | 0.00% | 0.0% |
| Q4 2021 | $1,961,355,000 | +56.2% | 63,188 | +22.0% | 0.00% | 0.0% |
| Q3 2021 | $1,255,543,000 | +60.7% | 51,775 | -3.3% | 0.00% | – |
| Q2 2021 | $781,353,000 | -36.6% | 53,554 | +8.4% | 0.00% | -100.0% |
| Q1 2021 | $1,233,143,000 | +17.0% | 49,385 | +27.7% | 0.00% | – |
| Q4 2020 | $1,054,359,000 | – | 38,685 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |